A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
Xingsheng Hu(Capital Medical University), Yan Sun(Peking University), Fenlai Tan(Betta Pharmaceuticals (China)), Yinxiang Wang(Betta Pharmaceuticals (China)), Jintao He(Sichuan Cancer Hospital), Kewei Ma(Jilin University), Kejing Ying(Sir Run Run Shaw Hospital), Xueke Jia(Baoding People's Hospital), Changxuan You(Southern Medical University), Li Zhang(Tianjin Chest Hospital), Yiping Zhang(Henan Normal University), Shucai Zhang(Northeastern University), Aiqin Gu(Nantong University), Lieming Ding(Betta Pharmaceuticals (China)), Junye Wang(Sun Yat-sen University), Chang-Li Wang(Tianjin Medical University Cancer Institute and Hospital), Meina Wu(Shanxi Medical University), Shun Chang Jiao(People's Liberation Army No. 150 Hospital), Baohui Han(Shanghai Jiao Tong University)
Cited by 51
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2017|380